Search clinical trials for: persistent moderate to severe asthma

Total 477493 results

Novartis Pharmaceuticals

Completed

Efficacy and Safety of Omalizumab in Children (6 - < 12 Years) With Moderate-severe, Inadequately Controlled Allergic Asthma

Asthma

United States
DiMango, Emily, M.D.
Novartis; Genentech, Inc.

Completed

Efficacy of Omalizumab as Add on Therapy for Minority Patients With Moderate to Severe Asthma

Asthma

United States
MediciNova

Completed

Study Evaluating the Safety and Effects of MN-221 in Subjects With Moderate to Severe Asthma

Asthma

United States
Novartis
Genentech, Inc.

Completed

Safety and Tolerability of Omalizumab in Poorly Controlled Moderate to Severe Asthma Patients

Asthma
Novartis
Daiichi Sankyo Co., Ltd.

Completed

Long-Term Study of IGE025 in Moderate to Severe Bronchial Asthma.

Asthma

Japan
Novartis
Daiichi Sankyo Co., Ltd.

Completed

Study of Omalizumab in Moderate to Severe Bronchial Asthma

Asthma
Novartis

Completed

Efficacy and Safety of Omalizumab in Adults (18-70 Years) With Moderate to Severe Chronic Urticaria

Chronic Urticaria

Germany
Novartis

Completed

Study to Determine the Onset of Action of Indacaterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease

Germany, United States, Belgium, Hungary
Novartis Pharmaceuticals

Completed

A Crossover Study to Determine the 24 Hour Lung Function Profile of Indacaterol in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease

Spain, United States, Belgium
Novartis

Completed

A Crossover Study to Determine the Effect on Lung Function of Indacaterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD), Using Tiotropium as an Active Control

Chronic Obstructive Pulmonary Disease (COPD)

Spain, Germany, South Africa, Australia, Poland, New Zealand, Netherlands
Novartis

Completed

Omalizumab Use and Asthma-Related Quality of Life in Patients With Severe Persistent Allergic Asthma

Asthma

Brazil
SkyePharma AG

Completed

New Combination Inhaler (FlutiForm HFA MDI 100/10 µg and 250/10 µg) Versus Fluticasone and Formoterol Administered Alone, and Placebo in Patients With Moderate to Severe Asthma

Asthma

United States, Puerto Rico
SkyePharma AG
Abbott

Completed

A Phase 3, Multicenter, Open-label Continuation Study in Moderate to Severe Asthmatic Subjects Who Completed FlutiForm HFA pMDI Study SKY2028-3-005

Asthma

United States, Ukraine, Mexico, Peru, Romania
Novartis Pharmaceuticals
Genentech, Inc.

Completed

Observational and Epidemiologic Study of the Disease Course and Unmet Needs in Children With Symptomatic Moderate to Severe Allergic Asthma

Moderate to Severe Allergic Asthma

United States, Puerto Rico
Abbott

Completed

Adalimumab in Combination With Topical Treatment (Calcipotriol/Betamethasone) in Subjects With Moderate to Severe Psoriasis and Insufficient Response to Classic Systemic Treatment (BELIEVE)

Chronic Plaque Psoriasis

Belgium, Denmark, France, Germany, Spain, Sweden, Switzerland, Finland, Turkey, Italy, Czech Republic, Austria, Netherlands, United Kingdom, Greece
Assaf-Harofeh Medical Center

Unknown

The Effect on Small Airways of Addition of Theophylline as Inducer of Histone Deacilase Activity for Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD), Treated With Inhaled Steroids and Long Acting Beta Agonists (COPD)

COPD

Israel
AstraZeneca

Completed

Titratable Dosing in Moderate to Severe Asthmatics

Asthma
AstraZeneca

Completed

Adults With Moderate to Severe Asthma

Asthma
University of North Carolina, Chapel Hill
National Center for Complementary and Integrative Health (NCCIH)

Completed

Safety Study of a Vitamin E Supplement in Normal Volunteers and Those With Both Allergy and Asthma

Asthma

United States
AstraZeneca

Completed

NIS-observe Treatment Efficacy in Maintaining Symptoms Control in Moderate/Severe Asthma With Symbicort SMART

Moderate/Severe Asthma

Romania
AstraZeneca

Completed

Non-interventional Surveillance of Effectiveness of Symbicort® Maintenance And Reliever Therapy (Symbicort® SMART) in the Treatment of Moderate and Severe Asthma

Asthma

Croatia
Prometheus Laboratories

Completed

Study of COLAL-PRED to Treat Moderate to Severe Ulcerative Colitis

Colitis, Ulcerative

United States
Oxagen Ltd

Completed

OC000459 Dose Finding Study in Patients With Mild to Moderate Persistent Asthma

Mild to Moderate Persistent Asthma

Bulgaria, Russian Federation, Hungary, Romania, Ukraine, Poland
SkyePharma AG

Completed

New Combination Inhaler (FlutiForm HFA MDI 100/10 µg and 250/10 µg) in Patients With Asthma

Asthma

United Kingdom, Germany, Hungary, Poland, Romania
SkyePharma AG
Abbott; MDS Pharma Services

Completed

A Study Comparing the Safety and Efficacy of Fluticasone and Formoterol Combination (FlutiForm™) With Fluticasone or Flovent to Treat Moderate to Severe Asthma in Adolescents and Adults

Asthma

United States, Chile, Mexico, Peru, Romania, Hungary, South Africa, Ukraine, Poland, Argentina
Children's Hospital of Philadelphia
Novartis Pharmaceuticals

Completed

Combination Therapy for Atopic Dermatitis

Atopic Dermatitis

United States
Glenmark Pharmaceuticals Europe Ltd. (R&D)

Unknown

A Clinical Study of Oglemilast in Patients With Mild to Moderate Persistent Asthma

Asthma

India
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating Etanercept in Moderate to Severe Asthma

Asthma

United States
Hospital General de Requena

Completed

Effect of Spacer in Extrafine Formoterol-Beclomethasone Treatment to Asthma

Asthma

Spain
Pulmagen Therapeutics

Completed

Effect of ADC4022 Co-Administered With Budesonide on Pulmonary Inflammation in Subjects With Moderate to Severe COPD

Chronic Obstructive Pulmonary Disease

United Kingdom, Poland
All India Institute of Medical Sciences, New Delhi

Completed

Effect of Addition of Oral Montelukast to Standard Treatment in Acute Moderate to Severe Asthma in Children (Montelukast)

Bronchial Asthma

India
Sanofi

Completed

Efficacy and Safety of Fexofenadine in Mild to Moderate Persistent Asthma

Asthma

Poland, Russian Federation, Mexico, Hungary, Guatemala, United States, Costa Rica
Sanofi

Completed

Efficacy and Safety of Fexofenadine in Mild to Moderate Persistent Asthma

Asthma

Russian Federation, Mexico, Hungary, Poland, Guatemala, United States, Costa Rica
University of Mississippi Medical Center
Novartis

Completed

Study to Evaluate the Effect of Xolair(Omalizumab) on Improving the Tolerability of Specific Immunotherapy in Patients With at Least Moderate Persistent Allergic Asthma Inadequately Controlled With Inhaled Corticosteroids

Asthma

United States
Astellas Pharma Inc
Astellas Pharma Europe B.V.

Completed

Dose Response of Inhaled Tacrolimus in Patients With Moderate Persistent Asthma

Asthma, Bronchial | Bronchial Asthma

Russian Federation, Hungary, Germany, Poland, Bulgaria, Ukraine, Czech Republic
Genentech, Inc.

Completed

A Study to Evaluate the Safety and Efficacy of HAE1 in Subjects With Moderate to Severe Allergic Asthma

Allergic Asthma
Novartis

Completed

A Study to Assess the Efficacy of Inhaled Corticosteroid (ICS) Therapy in Moderate-Severe Bronchial Asthma

Bronchial Asthma

Germany
Symbollon Pharmaceuticals

Unknown

Study for Treatment of Moderate or Severe, Periodic, "Cyclic", Breast Pain

Pain | Fibrocystic Disease of Breast | Fibrocystic Changes of Breast | Fibrocystic Mastopathy

United States
Second Affiliated Hospital, School of Medicine,...

Not yet recruiting

Efficacy and Safety of Dupilumab in Combination With Tofacitinib in Moderate to Severe Adult AD Patients

Atopic Dermatitis
AstraZeneca

Recruiting

STEP: Phase IIIb Study of Benralizumab to Step-down Maintenance Therapy in Patients With Severe Eosinophilic Asthma (STEP)

Severe Eosinophilic Asthma

China
Hospital Universitario La Paz
Hospital Universitario del Henares, Madrid, Spain

Not yet recruiting

CPAP Effect on Lipid Profile and Hyperuricemia in Patients With Dyslipidemia and Moderate-severe Obstructive Sleep Apnea (CPAPLIP)

Dyslipidemias | Sleep Apnea | Hyperuricemia
AbbVie

Not yet recruiting

A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up)

Atopic Dermatitis
Shanghai Yueyang Integrated Medicine Hospital

Not yet recruiting

Clinical Study of Trilinolein Cream for Prevention of Relapse in Remission of Moderate-to-severe Atopic Dermatitis.

Atopic Dermatitis
RemeGen Co., Ltd.

Not yet recruiting

A Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus (REMESLE-2)

Systemic Lupus Erythematosus
Taichung Veterans General Hospital
Chang Gung Memorial Hospital; National Cheng-Kung University Hospital; E-DA Hospital and other collaborators

Recruiting

Taiwan Severe Asthma Biologic Registry (TARGET)

Asthma | Pulmonary Disease

Taiwan
Abivax S.A.

Not yet recruiting

Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease (ENHANCE-CD)

Moderately to Severely Active Crohn Disease
AstraZeneca

Recruiting

Patient Characteristics, Treatment Patterns and Outcomes of Patients Enrolled in the Tezepelumab Patient Access Programme; a Retrospective, Observational Medical Chart Review Conducted in UK Severe Asthma Centres (TPAP)

Severe Asthma

United Kingdom
Medical University of Lodz
Poznan University of Medical Sciences; Medical Research Agency, Poland; Clinical... and other collaborators

Not yet recruiting

Comparison of Ustekinumab, Infliximab and Combination Therapy in Moderately to Severely Active Ulcerative Colitis (COMBO-UC)

Inflammatory Bowel Diseases | Ulcerative Colitis
AstraZeneca

Not yet recruiting

Phase IIa Study Evaluating AZD7798 in Crohn's Disease (AMALTHEA)

Moderate to Severe Crohn's Disease

United States, Vietnam, Turkey, Malaysia, Taiwan, Spain, Germany, Italy, Chile, Slovakia, Brazil, Japan, Bulgaria, Ukraine, South Africa, Argentina, Australia, Romania, Austria, Mexico, Sweden
Qilu Pharmaceutical (Hainan) Co., Ltd.

Recruiting

Phase 3 Study of QLG2198 in Haemodialysis Chinese Adult Subjects With Moderate-to-Severe Pruritus

Uremic Pruritus

China

3

Subscribe